Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
Glenmark Pharmaceuticals has announced a voluntary recall in the US, pulling more than 88,000 bottles of Carvedilol (a high blood pressure drug) and 22,656 bottles of Theophylline (used for COPD) from the market. The affected products were manufactured at Glenmark’s Goa and Pithampur plants in India.
The US FDA flagged five Carvedilol lots after detecting N-Nitroso Carvedilol Impurity-1 (NNCI) levels above the permissible 4.0 ppm limit, and one Theophylline lot due to failure in dissolution tests. Both issues prompted Class II recalls, suggesting the risk of serious harm is remote but temporary or reversible side effects are possible.
Carvedilol is a beta-blocker for treating hypertension, while Theophylline helps manage asthma and COPD by relaxing airway muscles. Glenmark initiated the recalls earlier this month, emphasizing patient safety and regulatory compliance.
You May Interested In
2026-09-10
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Global Countries Impose Tariffs on Chinese Chemical Products
-
Rare Earth and Power: Strategic Probing Beneath the New U.S.–China Trade Framework
-
U.S. Chemical Tariff Deadline Nears as the Industry Faces Cost Repricing and Supply-Chain Adjustment
-
EU Finalizes Anti-Dumping Duties on Chinese Adipic Acid as Chemical Trade Enters a Rule-Intensive Phase
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
-
China's National Narcotics Control Commission Issues Important Notice: Beware of These 8 Chemicals Being Diverted for Drug Production
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Supplement Recall Puts Nutrition Ingredient Safety Back Under Pressure
-
Chemours Sells Its Former Titanium Dioxide Site in Taiwan: Turning a “White Powder” Factory into “Wind Power Real Estate” for $360 Million—Buying Not Cash, But Breathing Room
-
The “Counter-Wind Ledger” of CHF 11.2 Billion: Sika Barely Grew in 2025—Yet Kept Taking Market Share
Recommend Reading
-
![Metso Expands Wear Parts Capacity in China with New Rubber Factory in Quzhou]()
Metso Expands Wear Parts Capacity in China with New Rubber Factory in Quzhou
-
![Steel in the Hourglass: Germany’s “Protect-Steel” Proposal and the Green Calculation Behind It]()
Steel in the Hourglass: Germany’s “Protect-Steel” Proposal and the Green Calculation Behind It
-
![DKSH Expands Partnership with Assessa to Distribute Botanical Ingredients Across China]()
DKSH Expands Partnership with Assessa to Distribute Botanical Ingredients Across China
-
![EU May Build Industry-Level Trade Barriers Against Chinese Chemicals]()
EU May Build Industry-Level Trade Barriers Against Chinese Chemicals
-
![EU Low-Value Parcel Rules Could Disrupt Chemical Sample Flows]()
EU Low-Value Parcel Rules Could Disrupt Chemical Sample Flows
-
![January 15 Isopropanol Market Trend Upward in China]()
January 15 Isopropanol Market Trend Upward in China
-
![Premium Global Chemical Sourcing Requests (6-9Aug, 2026)]()
Premium Global Chemical Sourcing Requests (6-9Aug, 2026)
-
![Polyethylene Has Risen Strongly Since January]()
Polyethylene Has Risen Strongly Since January
-
![Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials]()
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
![Premium Global Chemical Sourcing Requests (8-12 Dec 2025)]()
Premium Global Chemical Sourcing Requests (8-12 Dec 2025)
